Abstract
Mitral valve regurgitation (MR) affects approximately 4 million people in the United States alone, increasing in prevalence with age. Approved by the Food and Drug Administration (FDA) in October 2013, percutaneous edge-to-edge transcatheter mitral valve repair (also known as the MitraClip system) has been used in over 40,000 patients globally. Additionally, there is keen interest and early exploration into the use of MitraClip for treatment of severe symptomatic tricuspid regurgitation, another undertreated disease with significant morbidity and mortality. In this manuscript, we aim to review the current indications, procedural details as well as emerging indications for this novel technology.
Keywords:
MitraClip; mitral regurgitation; transcatheter repair; tricuspid regurgitation.
Copyright © 2018 Elsevier Inc. All rights reserved.
MeSH terms
-
Cardiac Catheterization / adverse effects
-
Cardiac Catheterization / instrumentation*
-
Cardiac Catheterization / mortality
-
Cardiac Surgical Procedures / adverse effects
-
Cardiac Surgical Procedures / instrumentation*
-
Cardiac Surgical Procedures / mortality
-
Echocardiography, Doppler, Color
-
Echocardiography, Three-Dimensional
-
Echocardiography, Transesophageal
-
Hemodynamics
-
Humans
-
Mitral Valve / diagnostic imaging
-
Mitral Valve / physiopathology
-
Mitral Valve / surgery*
-
Mitral Valve Insufficiency / diagnostic imaging
-
Mitral Valve Insufficiency / mortality
-
Mitral Valve Insufficiency / physiopathology
-
Mitral Valve Insufficiency / surgery*
-
Recovery of Function
-
Risk Factors
-
Treatment Outcome
-
Tricuspid Valve / diagnostic imaging
-
Tricuspid Valve / physiopathology
-
Tricuspid Valve / surgery*
-
Tricuspid Valve Insufficiency / diagnostic imaging
-
Tricuspid Valve Insufficiency / mortality
-
Tricuspid Valve Insufficiency / physiopathology
-
Tricuspid Valve Insufficiency / surgery*